DACTINOMYCIN

First approved in 1964

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C62H86N12O16
Molecular Weight	1255.417
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C3=C4N=C5C(OC4=C(C)C=C3)=C(C)C(=O)C(N)=C5C(=O)N[C@H]6[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]7([H])CCCN7C(=O)[C@H](NC6=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C

InChI

InChIKey=RJURFGZVJUQBHK-IIXSONLDSA-N

InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C62H86N12O16
Molecular Weight	1255.417
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954

Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278 Target ID: CHEMBL2311221 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Binding Agent 1064		156.25 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Wilms' tumor 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8429	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Childhood rhabdomyosarcoma 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8429	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Metastatic nonseminomatous testicular cancer 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8429	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Ewing’s sarcoma 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8429	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Gestational trophoblastic neoplasia 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8429	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Locally recurrent and locoregional sarcomas 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Palliative	Approved 8429	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Locally recurrent and locoregional carcinomas 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Palliative	Approved 8429	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Locally recurrent and locoregional adenocarcinomas 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Palliative	Approved 8429	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964

C_max

Value	Dose	Co-administered	Analyte	Population
30.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
25.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931	1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered:		DACTINOMYCIN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
142.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.67 μg × min/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931	1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered:		DACTINOMYCIN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
28.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931	1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered:		DACTINOMYCIN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	Other AEs: Pancytopenia, Mucositis... Other AEs: Pancytopenia (1 patient) Mucositis (severe, 1 patient) Pancreatitis (1 patient) Hyponatremia (1 patient) Hypocalcemia (1 patient) Respiratory distress (1 patient) Melena (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
0.15 ug/kg multiple, intravenous (total) Highest studied dose Dose: 0.15 ug/kg Route: intravenous Route: multiple Dose: 0.15 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/1139861	unhealthy, 40-77 years n = 2 Health Status: unhealthy Condition: malignant melanoma Age Group: 40-77 years Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/1139861	Sources: https://pubmed.ncbi.nlm.nih.gov/1139861
1.5 mg/m2 single, intravenous Highest studied dose Dose: 1.5 mg/m2 Route: intravenous Route: single Dose: 1.5 mg/m2 Sources: https://pubmed.ncbi.nlm.nih.gov/14522028	unknown, children n = 1 Health Status: unknown Age Group: children Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/14522028	Sources: https://pubmed.ncbi.nlm.nih.gov/14522028

AEs

AE	Significance	Dose	Population
Hypocalcemia	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Hyponatremia	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Melena	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Pancreatitis	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Pancytopenia	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Respiratory distress	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Mucositis	severe, 1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10531579

Sourcing

Vendor/Aggregator	ID	URL
Achemtek	0104-058162	http://www.achemtek.com/50-76-0
Acorn PharmaTech	ACN-036884	http://www.acornpharmatech.com/
Ambinter	Amb19930304	http://www.ambinter.com/reference/19930304
Aurora Fine Chemicals LLC	A17.878.164	http://online.aurorafinechemicals.com/info?ID=A17.878.164
AvaChem Scientific	4693	http://www.avachem.com/productSearch.asp?4693
Avantor Inc	101096-738	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101096-738
Avantor Inc	200036-466	https://us.vwr.com/store/product/18601366/actinomycin-d
BOC Sciences	50-76-0	https://adc.bocsci.com/product/actinomycin-d-cas-50-76-0-1293.html
Chemspace	CSSB02125550997	https://chem-space.com/CSSB02125550997
Glentham Life Sciences	GA0481	http://www.glentham.com/products/product/GA0481/
OChem	10380	http://www.ocheminc.com/index.php?act=psearch&pid=050A760
Selleck Chemicals	S8964	http://www.selleckchem.com/products/actinomycin-d.html
Sigma-Aldrich	01815_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/01815?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A1410_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a1410?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A4262_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a4262?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A9415_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a9415?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1162400_USP	https://www.sigmaaldrich.com/catalog/product/usp/1162400?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S548606	http://www.smolecule.com/products/s548606
THE BioTek	bt-288011	https://www.thebiotek.com/product/inhibitors/bt-288011
VladaChem	VL272217-10MG	https://www.vladachem.com/product.php?products=50-76-0
abcr GmbH	AB353527	http://www.abcr.de/shop/en/AB353527
eNovation Chemicals	D371034	http://www.enovationchem.com/productDetails.asp?productID=D371034
iChemical	EBD32182	http://www.ichemical.com/products/50-76-0.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids.	1999 Apr	10100995
Rapid nucleolytic degradation of the small cytoplasmic Y RNAs during apoptosis.	1999 Aug 27	10455152
VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism.	2000 Apr	10751333
Testin induction: the role of cyclic 3',5'-adenosine monophosphate/protein kinase A signaling in the regulation of basal and lonidamine-induced testin expression by rat sertoli cells.	2000 Dec	11090432
Carcinogenic nickel induces genes involved with hypoxic stress.	2000 Jan 1	10646848
Experimental model of hepatic venoocclusive disease (VOD) caused by dactinomycin--preliminary report about hepatoprotective effect of amifostine.	2000 May-Jun	11208352
Amphetamine induces differential changes in the gene expression of metabotropic glutamate receptor 5 in cultured cortical and hippocampal neurons.	2001 Aug	11665859
The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts.	2001 Feb	11216681
Cadmium-induced cell transformation and tumorigenesis are associated with transcriptional activation of c-fos, c-jun, and c-myc proto-oncogenes: role of cellular calcium and reactive oxygen species.	2001 Jun	11353138
Differential induction of rat hepatic cytochromes P450 3A1, 3A2, 2B1, 2B2, and 2E1 in response to pyridine treatment.	2001 Mar	11181506
Dual phases of functional change in norepinephrine transporter in cultured bovine adrenal medullary cells by long-term treatment with clozapine.	2001 May	11359867
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.	2002 Dec 1	12430140
Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole.	2002 Jan	11752201
Reactive oxygen species alter gene expression in podocytes: induction of granulocyte macrophage-colony-stimulating factor.	2002 Jan	11752025
Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity.	2002 Jan 1	11756511
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation.	2003 Mar 15	12479793
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells.	2003 May 15	12704794
The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.	2003 Oct	12869419
Morphine suppresses lymphocyte apoptosis by blocking p53-mediated death signaling.	2003 Sep 5	12927789
Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes.	2004 Dec	15610522
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.	2004 Dec 1	15572759
DEP-induced fra-1 expression correlates with a distinct activation of AP-1-dependent gene transcription in the lung.	2004 Feb	14565943
Endosulfan-mediated biochemical changes in the freshwater fish Clarias batrachus.	2004 Mar	15202864
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.	2004 Nov	15314095
Coordinated secretion of alkaline phosphatase into serum and intestine in fat-fed rats.	2004 Sep-Oct	15599000
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells.	2005 Feb 10	15592511
Promoting insulin secretion in pancreatic islets by means of bisphenol A and nonylphenol via intracellular estrogen receptors.	2005 May	15778011

Patents

Sample Use Guides

In Vivo Use Guide

Wilms’ Tumor, Childhood Rhabdomyosarcoma and Ewing’s Sarcoma: Regimens of 15 mcg/kg intravenously daily for five days administered in various combinations and schedules with other chemotherapeutic agents; Metastatic Nonseminomatous Testicular Cancer: 1000 mcg/m2 intravenously on Day 1 as part of a combination regimen with cyclophosphamide, bleomycin, vinblastine, and cisplatin; Gestational Trophoblastic Neoplasia: 12 mcg/kg intravenously daily for five days as a single agent. 500 mcg intravenously on Days 1 and 2 as part of a combination regimen with etoposide, methotrexate, folinic acid, vincristine, cyclophosphamide and cisplatin; Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies: 50 mcg (0.05 mg) per kilogram of body weight for lower extremity or pelvis, 35 mcg (0.035 mg) per kilogram of body weight for upper extremity.

Route of Administration: Intravenous

In Vitro Use Guide

Human osteosarcoma cell line MG63 were incubated with dactinomycin (actinomycin D) at final concentrations of 0.1, 0.5, 1 and 5 uM during 0, 2, 6 and 24 hours. The drug was shown to inhibit the proliferation of cells by decreasing cyclin gene transcriptions.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:14:37 GMT 2023` Edited by `admin` on `Sat Dec 16 16:14:37 GMT 2023`
Record UNII	1CC1JFE158
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DACTINOMYCIN

Official Name

English

DACTINOMYCIN [HSDB]

Common Name

English

ACTINOMYCIN C1

Common Name

English

ACTINOMYCIN D [WHO-IP]

Common Name

English

DACTINOMYCIN [WHO-IP]

Common Name

English

3H-PHENOXAZINE-1,9-DICARBOXAMIDE, 2-AMINO-N,N'-BIS(HEXADECAHYDRO-6,13-DIISOPROPYL-2,5,9-TRIMETHYL-1,4,7,11,14-PENTAOXO-1H-PYRROLO(2,1-I)(1,4,7,10,13)OXATETRAAZACYCLOHEXADECIN-10-YL)-4,6-DIMETHYL-3-OXO-

Common Name

English

ACTINOMYCIN-D

Common Name

English

ACTINOMYCIN I1

Common Name

English

DILACTONE ACTINOMYCIN D ACID

Common Name

English

ACTINOMYCIN D [JAN]

Common Name

English

DACTINOMYCIN [USP-RS]

Common Name

English

GNF-PF-2290

Code

English

DACTINOMYCIN [USP MONOGRAPH]

Common Name

English

ACTINOMYCIN D [IARC]

Common Name

English

DACTINOMYCIN [MART.]

Common Name

English

DACTINOMYCIN [USAN]

Common Name

English

DACTINOMYCIN [VANDF]

Common Name

English

MERACTINOMYCIN

Common Name

English

Dactinomycin [WHO-DD]

Common Name

English

ACTINOMYCIN X1

Common Name

English

DACTINOMYCINUM [WHO-IP LATIN]

Common Name

English

DACTINOMYCIN [MI]

Common Name

English

DACTINOMYCIN [ORANGE BOOK]

Common Name

English

N,N'-((2-AMINO-4,6-DIMETHYL-3-OXO-3H-PHENOXAZINE-1,9-DIYL)-BIS(CARBONYLIMINO(2-HYDROXYPROPYLIDENE)CARBONYLIMINOISOBUTYLIDENECARBONYL-1,2-PYRROLIDINEDIYLCARBONYL(METHYLIMINO)METHYLENECARBONYL))BIS(N-METHYL-L-VALINE) DILACTONE

Common Name

English

NSC-3053

Code

English

Actinomycin D

Common Name

English

NCI-C04682

Code

English

ACTINOMYCIN IV

Common Name

English

dactinomycin [INN]

Common Name

English

ONCOSTATIN K

Common Name

English

COSMEGEN

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C204